GUFICBIO Intraday Analysis...

GUFICBIO Share Price

Open 89.95 Change Price %
High 91.50 1 Day 1.00 1.14
Low 87.55 1 Week 1.85 2.12
Close 89.00 1 Month 4.30 5.08
Volume 185098 1 Year 47.40 113.94
52 Week High 99.60
52 Week Low 40.10
GUFICBIO Important Levels
Resistance 2 92.66
Resistance 1 91.15
Pivot 89.35
Support 1 86.85
Support 2 85.34
NSE INDIA Most Active Stocks
HDFCLIFE 344.60 18.83%
RCOM 12.10 3.42%
HDIL 63.95 7.03%
JPASSOCIAT 18.65 -0.27%
RTNPOWER 7.60 5.56%
BANKBARODA 183.55 0.41%
SUZLON 13.70 1.86%
PNB 190.80 0.63%
SBIN 337.50 1.23%
DLF 223.85 7.26%
NSE INDIA Top Gainers Stocks
SUNDARAM 4.20 20.00%
NAGAROIL 3.90 20.00%
PKTEA 229.90 19.99%
PROVOGE 5.75 19.79%
HDFCLIFE 344.60 18.83%
ZUARIGLOB 227.70 14.42%
RENUKA 17.55 13.96%
MAHASTEEL 69.10 13.84%
BALAMINES 613.10 13.60%
PATINTLOG 87.90 12.84%
NSE INDIA Top Losers Stocks
VIPCLOTHNG 54.30 -14.01%
SAMTEL 0.45 -10.00%
LSIL 2.05 -8.89%
WSI 6.40 -7.91%
NBIFIN 2752.40 -6.70%
PRADIP 2.20 -6.38%
MOHITIND 47.55 -6.12%
CUBEXTUB 30.40 -5.00%
PINCON 38.00 -5.00%
STCINDIA 207.20 -5.00%

Gufic Biosciences Limited (NSE: GUFICBIO)

GUFICBIO Technical Analysis 4
As on 17th Nov 2017 GUFICBIO Share Price closed @ 89.00 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 68.70 & Buy for SHORT-TERM with Stoploss of 81.45 we also expect STOCK to react on Following IMPORTANT LEVELS.
GUFICBIO Target for November
1st Target up-side 101.53
2nd Target up-side 108.98
3rd Target up-side 116.43
1st Target down-side 80.27
2nd Target down-side 72.82
3rd Target down-side 65.37
GUFICBIO Synopsis Technicals View
50 Day EMA Close is Above EMA 50 (Short Term)
100 Day EMA Close is Above EMA 100 (Mid Term) Bullish
200 Day EMA Close is Above EMA 200 (Long Term) Bullish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 55.36 Sideways
MFI (14) MFI is 54.36 Sideways
CCI (20) CCI is 1.10 Sideways
WILLIAM %R (14) William %R is -51.75 Sideways
ADX (14) ADX is Above 20 & +DI is Above -DI Up Trend
PSAR Stoploss For Short Sell 98.96
10 Day Avg Volume Traded 50.01 % More then 10 Day Average Volume
GUFICBIO Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Drug Manufacturers - Major
Offical website
Kamala Bhavan II
Shop - 37, First Floor
Mumbai, 400069
GUFICBIO Latest News
Limited Review for Dec 31, 2014   Hindu Business Line   - 03rd Mar 15
Proposed Bank Strikes   Hindu Business Line   - 17th Feb 15
Gufic Bio standalone Dec '14 sales at Rs 34.34 crore   - 17th Feb 15
BSE Breaches 25.8k Mark; Metals, Goods, Auto and Power Stocks Fall   International Business Times, India Edition   - 04th Jul 14
NPPA sends notices in 89 cases of overcharging to recover   - 22nd Apr 14
Gufic BioSciences Ltd Recommends Dividend   Reuters Key Development   - 31st May 13
Cops hunt for fake drug maker   Times of India   - 24th Feb 09
Interactive Technical Analysis Chart Gufic Biosciences Limited ( GUFICBIO NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from
Your Comments and Response on Gufic Biosciences Limited
GUFICBIO Business Profile
Gufic Biosciences (GUFICBIO) is a pharmaceuticals and biosciences company. Incorporated in 1984 as Central Finance, the company got its current name on Jun. 05, 2000. The company operates in the segments of pharma, healthcare, bio-technology, seeds, herbal, R&D, and bulk drugs. The company provides pharma medicines for diarrhoea (Ridol), episiotomy (Zad-g), anemia (Optifer), infections (Lotril), inflammation (Valsafe)...etc. The healthcare segment provides consumer and personal hygiene products like roll-ons for cold and sanitary napkins like Shapers. The biotechnology segment produces high-yielding and elite planting material of medicinal and other herbal plants using tissue culture techniques. The tissue culture facility produces five million plants per annum. The company has two green houses of 800 sq. m. Production includes banana, potato, sugarcane, date palm, jatropha, and bixa (source of natural food color). It brings out hybrid varieties of major vegetable seeds like tomato, chilli, cabbage, cauliflower, capsicum, coriander, bhendi, bottle gourd, bitter gourd, ridge gourd, brinjal, cucumber and watermelon. The company provides herbal and ayurvedic medicines for muscular pains (Sallaki); menstrual excesses (Eugynin); hyperacidity, gastritis, and chronic fungal dyspepsia (Zulcer), aches and pains (Rumastal-forte), liver problems (Livpar), constipation (Laxive), and cough (Kofend Syrup). Bulk drugs include anesthetics (lidocaine), antifungals (econazole, miconazole, ketokonazole), antiielmintic (mebendazole, polymorph), cathartic (castor oil), and food colors. The company has its facilities in Vile Parle, Mumbai and a plant in Navsari, Gujarat. The R&D Centre is a state-of-the-art research laboratory and provides total product development by developing new pharmaceutical products, new drug delivery systems, and new platform technologies. The functional areas are formulation development, analytical development, packaging development and documentation. The current market capitalization stands at Rs 44.48 crore. The company has reported a standalone sales of Rs 29.03 crore and a Net Profit of Rs 1.15 crore for the quarter ended September 2013. The company management includes Jayesh P Choksi - Chairman & Managing Director, Pranav J Choksi - Executive & Wholetime Director, M G Dhapalapur - Executive & Wholetime Director, Sharat S Gandhi - Ind. Non-Executive Director, Ashok M Tarale - Ind. Non-Executive Director, Khantilal N Sanghavi - Ind. Non-Executive Director, Pankaj J Gandhi - Additional Director, Jagdish D Shah - Additional Director. The Registered office is at Shop - 37, First Floor, Kamala Bhavan II, Swami Nityanand Road, Mumbai, Maharashtra - 400069.